Compare · LFST vs WGS
LFST vs WGS
Side-by-side comparison of LifeStance Health Group Inc. (LFST) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LFST and WGS operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- LFST is the larger of the two at $5.26B, about 2.8x WGS ($1.86B).
- LFST has been more active in the news (7 items in the past 4 weeks vs 5 for WGS).
- LFST has more recent analyst coverage (17 ratings vs 8 for WGS).
- Company
- LifeStance Health Group Inc.
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $5.26B
- $1.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 7
- 5
- Recent ratings
- 17
- 8
LifeStance Health Group Inc.
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics. It offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. The company offers patients care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was incorporated in 2021 and is based in Scottsdale, Arizona.
Latest LFST
- SEC Form 10-Q filed by LifeStance Health Group Inc.
- LifeStance Health Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook
- /C O R R E C T I O N - LifeStance Health/
- LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows
- SEC Form 8-K filed by LifeStance Health Group Inc.
- LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026
- Nearly Half of Americans Say Fear of an Unwanted Viral Moment Keeps Them from Being Themselves in Public, LifeStance Survey Finds
- Chief Executive Officer Bourdon David gifted 300,000 shares and received a gift of 300,000 shares, decreasing direct ownership by 24% to 948,247 units (SEC Form 4)
- Large owner Tpg Gp A, Llc sold $226,255,274 worth of shares (18,409,705 units at $12.29) (SEC Form 4)
Latest WGS
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
- GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
- GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
- GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
- GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
- GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)
- Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)